Studying MHC Class II Peptide Loading and Editing In Vitro.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2019
Historique:
entrez: 1 6 2019
pubmed: 31 5 2019
medline: 23 1 2020
Statut: ppublish

Résumé

HLA-DM is now known to have a major contribution to the selection of immunodominant epitopes. A better understanding of the mechanisms controlling epitope selection can be achieved by examination of the biophysical behavior of MHC class II molecules upon binding of antigenic peptides and of the effect of DM on the interactions. Using purified soluble molecules, in this chapter we describe several in vitro methods for measuring peptide binding to HLA-DR molecules and the effects of HLA-DM on this interaction. A simple qualitative method, Gentle SDS-PAGE Assay assesses the ability of peptides to form tight complexes with MHC class II molecules. Measuring binding kinetics is among the most informative approaches to understanding molecular mechanisms, and here we describe two different methods for measuring binding kinetics of peptide-MHC complexes. In one method, rates of association and dissociation of fluorescently labeled peptides to soluble MHC class II molecules can be determined using G50 spin columns to separate unbound peptides from those in complex with MHC molecules. In another method, association and dissociation of unlabeled peptides and MHC class II molecules can be determined in real time using BIAcore Surface Plasmon Resonance (SPR). We also describe an intrinsic tryptophan fluorescence assay for studying transient interactions of DM and MHC class II molecules.

Identifiants

pubmed: 31147951
doi: 10.1007/978-1-4939-9450-2_24
doi:

Substances chimiques

HLA-DR Antigens 0
Histocompatibility Antigens Class II 0
Peptides 0
Tryptophan 8DUH1N11BX

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

343-355

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI063764
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI091923
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI101987
Pays : United States

Auteurs

AeRyon Kim (A)

Department of Inflammation and Oncology, Amgen Research, Amgen Inc., South San Francisco, CA, USA.

Isabel Emiko Ishizuka (IE)

Department of Immunology, Genentech Inc., South San Francisco, CA, USA.

Isamu Z Hartman (IZ)

Office for Technology Development, UT Southwestern Medical Center, Dallas, TX, USA.

Yuri Poluektov (Y)

MBL International, A JSR Life Sciences Company, Des Plaines, IL, USA.

Kedar Narayan (K)

Center for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Scheherazade Sadegh-Nasseri (S)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ssadegh@jhmi.edu.
Department of Biology, Johns Hopkins University, Baltimore, MD, USA. ssadegh@jhmi.edu.
Graduate Program in Immunology, Johns Hopkins University, Baltimore, MD, USA. ssadegh@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH